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Abstract Deficiency of the cytosolic enzyme thymidine
phosphorylase (TP) causes a multisystem disorder called
mitochondrial neurogastrointestinal encephalomyopathy
(MNGIE) syndrome. Clinical symptoms are gastrointestinal
dysfunction, muscle involvement and neurological deterio-
ration. TP deficiency is biochemically characterised by
accumulation of thymidine and deoxyuridine in body fluids
and compromised mitochondrial deoxyribose nucleic acid
(mtDNA) integrity (depletion and multiple deletions). In
this report we describe a patient with the clinical and
biochemical features related to the end stage of the disease.
Home parenteral nutrition had started to improve the
clinical condition and preparations were initiated for stem
cell transplantation (SCT) as a last resort treatment.
Unfortunately, the patient died during the induction phase
of SCT. This report shows that TP deficiency is a severe
clinical condition with a broad spectrum of affected tissues.
TP deficiency can be easily determined by the measurement
of pyrimidine metabolites in body fluids and TP activity in
peripheral blood leucocytes. Early detection and treatment
may prevent the progress of the clinical symptoms and,
therefore, should be considered for inclusion in newborn
screening programmes.
Abbreviations
BMI body mass index
CIPO chronic intestinal pseudo-obstruction
DPD dihydropyrimidine dehydrogenase
EMA ethylmalonic acid
ESI electrospray ionisation
GI gastrointestinal
HLA human leucocyte antigen
MNGIE mitochondrial neurogastrointestinal
encephalomyopathy
MRM multiple reaction mode
mtDNA mitochondrial deoxyribose nucleic acid
OXPHOS oxidative phosphorylation
SCT stem cell transplantation
TP thymidine phosphorylase
WBC white blood cell
Introduction
In the 1990s thymidine phosphorylase (TP; EC 2.4.2.4 )
deficiency was identified as the most common cause of the
clinical syndrome called mitochondrial neurogastrointestinal
encephalomyopathy (MNGIE; OMIM 603041) (Nishino et al.
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2000). As indicated in this acronym, TP deficiency affects
several tissues (Table 1) (Nishino et al. 2001).
Although TP deficiency is a multisystem disease, the
gastrointestinal problems are the most prominent and, in the
majority of cases, are the presenting symptoms. Visceral
manifestations are caused by mitochondrial dysfunction of
the intestinal smooth muscle, and the mitochondrial
abnormalities in oesophageal and small intestine biopsies
were identical to the aberrations observed in skeletal muscle
of patients with other mitochondrial diseases (Blondon et
al. 2005; Giordano et al. 2008). Neurological symptoms are
often mild, although, initially, magnetic resonance imaging
(MRI) of the brain does not always reveal a leucoencephal-
opathy; ultimately, all patients develop leucoencephalop-
athy. The clinical picture develops gradually in the course
of life, and mild cases can easily be misdiagnosed,
especially when the symptoms are not recognised as part
of a syndrome (Teitelbaum et al. 2002).
When a mitochondrial disease is being considered,
biochemical investigations often include measurement of
the respiratory chain capacity in a muscle biopsy. A
reduction in the overall oxidative phosphorylation
(OXPHOS) capacity of the mitochondria can be observed
in MNGIE, as well as decreased activity of the enzymes of
the respiratory chain having mitochondrial deoxyribose
nucleic acid (mtDNA)-encoded subunits (Marti et al.
2003). At the level of mtDNA, a decreased amount
(depletion) and a loss of integrity (multiple mtDNA
deletions) are observed, indicating a defect in mtDNA
maintenance. Additional laboratory investigations show
elevated concentrations of thymidine and deoxyuridine in
all body fluids (Marti et al. 2003). The TP activity in
MNGIE patients with homozygous or compound heterozy-
gous TP mutations is normally barely detectable, whilst the
activity is approximately 30% of control values in heterozy-
gous carriers (Marti et al. 2004). Today, over 30 different
mutations have been identified in the gene encoding TP,
TYMP (GenBank no. NM_001953) (Laforce et al. 2009;
Marti et al. 2005; Nishino et al. 2000).
Clinical history
At the age of 16 the patient was investigated because of
frequent episodes of diarrhoea. At that time no gastrointestinal
(GI) abnormalities were noted. Ten years later his GI
symptoms had worsened and his overall clinical condition
was poor. His body weight was 58 kg, resulting in a bodymass
index (BMI) of 16.6. During the following years frequent
episodes of (micro)perforation of the intestinal tract resulted in
resection of a part of the proximal jejunum. Furthermore,
perforation of the sigmoid was diagnosed and was followed by
a new resection of the affected part of the intestinal tract.
Neurological investigations showed generalised muscle
areflexia, bilateral ptosis and the beginnings of ophthalmople-
gia. At that time MRI revealed massive supra- and infratento-
rial demyelinisation, although the leucoencephalopathy was
asymptomatic. Investigations of a muscle biopsy showed a
predominance of type 1 fibres; type 2 fibres were scarcely
visible. Aberrations in the type 1 fibres (accumulation of lipid,
glycogen depletion, myophagia), peripheral location of the
mitochondria and excessive succinate dehydrogenase (SDH)
activity in most fibres supported the diagnosis of a mitochon-
driopathy. Mutation analysis for TP was initiated and revealed
a homozygous A to C transition in exon 7 (A3371C) (Nishino
et al. 2000).
In the following years the gastrointestinal problems
worsened, resulting in chronic intestinal pseudo-obstruction
(CIPO) with gastroparesia. Because of a further decrease in
the BMI to 14.3, home parenteral nutrition was started. MRI
Clinical symptom Proband Literature (Nishino et al. 2001)
Cachexia + +
Gastrointestinal manifestations + +
Borborygmi + +
Abdominal pain + +
Diarrhoea + +
Diverticulosis + +
Pseudo-obstruction + +
Neurological manifestations + +
Ptosis + +
Ophthalmoplegia + +
Peripheral neuropathy + +
Hearing loss + +
Depression + Unknown
Table 1 Clinical features of our
patient compared with those in
the literature
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showed cerebral ventriculomegaly, when compared to MRI
images made 5 years earlier. Ptosis was still prominent, with
decreased eye movements (ophthalmoplegia). Only at this
time did the myopathy become clinically relevant. The family
history revealed a sister with a clinical history of anorexia,
denutrition, neurological problems and depression, who died
in her thirties. Most probably this was a case of TP deficiency
too. Other family members reported no clinical problems
related to TP deficiency.
To slow down the progression of the disease, stem cell
transplantation (SCT) was considered. Family members were
screened for human leucocyte antigen (HLA) genotype, TP
activity and the genetic defect in the TYMP gene: both
siblings were heterozygous carriers of the TYMP mutation
and had TP activities in the heterozygous carrier range, but
only one had an HLA genotype compatible with that of the
patient. The patient was prepared for SCT, but unfortunately
died during the induction phase of the chemotherapy.
Biochemical, enzymological and DNA investigations
Purine and pyrimidine metabolites in body fluids were
analysed with liquid chromatography–tandem mass spec-
trometry (LC-MSMS) (Waters Micromass Quattro Micro).
Purines and pyrimidines were detected in both electrospray
ionisation (ESI)-positive mode and ESI-negative mode
using multiple reaction monitoring (MRM). Thymidine
phosphorylase activity was measured in isolated peripheral
blood leucocytes, as described before (van Kuilenburg and
Zoetekouw 2005). Briefly, lysed leucocytes (2.5—30 µg
protein) were incubated with 2 mM thymidine at 37°C , pH 7.4
for 60 min. After termination of the reaction with perchloric
acid, the samples were centrifuged, and the supernatant was
neutralised and analysed by high-performance liquid chroma-
tography (HPLC). Thymine concentrations were calculated
against standard concentrations of thymine. Dihydropyrimidine
dehydrogenase (DPD, EC 1.3.1.2.) activity was determined
using incubation with 14C-labelled thymine as described
before (Van Kuilenburg et al. 1997). Reference values for
TP and DPD activity and pyrimidine metabolites in body
fluids were established using samples originating from
patients without MNGIE (n=25).
Screening for the familial mutation in exon 7 of the TYMP
gene in the family members was done as described before
(Nishino et al. 2000), with the exception that a different set
of primers was used: forward primer TGGCAACCCA
GGGTGCAGCA and reverse primer GGGCGGGGACGGG
TCTTAG.
Results
Thymidine and deoxyuridine concentrations in the urine
and plasma of the patient were strongly elevated (Table 2).
In addition, analysis of purine and pyrimidine metabolites
revealed an elevated excretion of thymine and uracil:
23 µmol/mmol creatinine and 51 µmol/mmol creatinine,
respectively (reference values <1 µmol/mmol creatinine
and 1.0–14 µmol/mmol creatinine). Dihydropyrimidines
were not detectable. In plasma, uracil and thymine were
undetectable. Thymidine and deoxyuridine were not detect-
able in the plasma of the parents and the siblings.
Amino acid analysis in the patient showed a mild
generalised hyperaminoaciduria; furthermore, the excretion
of ethylmalonic acid (EMA) and creatine was slightly
elevated (data not shown).
TP activity in peripheral white blood cells (WBCs) of
the patient was consistent with the diagnosis MNGIE
(Table 2). TP activity in the parents and siblings of the
patient were in the heterozygous carrier range.
The presence of thymine and uracil urged us to measure
DPD activity. The specific DPD activity in the patient was in
the normal range, at 16.04 nmol/mg protein per hour [reference
values (n=24) 16.54±4.57 nmol/mg protein per hour] in
lymphocytes. Sequencing of the TYMP gene revealed that the
proband was homozygous for a c.866A>C mutation in
exon 7, resulting in the substitution of glutamic acid by
Table 2 TP activities in leucocytes and metabolite concentrations in body fluids of the proband and family members
Subject TP activity (nmol/mg
protein per hour)
Thymidine in
plasma (µmol/l)
Deoxyuridine in
plasma (µmol/l)
Thymidine in urine
(µmol/mmol creatinine)
Deoxyuridine in urine
(µmol/mmol creatinine)
Proband 10 10 20 29 51
Father 200 n.d. n.d.
Mother 320 n.d. n.d.
Sister 300 n.d. n.d.
Brother 260 n.d. n.d.
Reference 360–830 <0.1 <0.1 <5 <1
n.d., not detectable
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alanine at position 289 of the protein (p.E289A). The
siblings and both parents were heterozygous carriers for
this mutation.
Discussion
Deficiency of thymidine phosphorylase consistently results
in elevated concentrations of thymidine and deoxyuridine
in body fluids (Marti et al. 2004). The excess availability
of, especially, thymidine causes an intracellular (intra-
mitochondrial) imbalance in deoxynucleotide triphosphates,
leading to disturbances in mtDNA replication and mainte-
nance. This results in reduced mtDNA copy number
(depletion) and multiple deletions in the mtDNA, which
affect the enzymes involved in oxidative phosphorylation
(Lopez et al. 2009; Pontarin et al. 2006). Investigations of
muscle confirmed the presence of a mitochondriopathy.
Elevated EMA excretion is suggestive of malfunction of
the mitochondrial electron transport system. Proximal
tubulopathy, often associated with mitochondrial disease, may
be the cause of the mild hyperaminoaciduria in our patient.
We observed an increased excretion of thymine and
uracil in our patient, which has been described before
(Fairbanks et al. 2002). Because of the normal activity of
DPD and the absence of dihydropyrimidines and N-
carbamoyl amino acids, a defect in pyrimidine degradation
does not seem plausible. The bi-directionality of TP might
partly explain the elevated excretion of thymine and uracil
(Temmink et al. 2007).
Therapy for TP deficiency is still not well established.
Dialysis and platelet infusions have been used, both
unsuccessful in the attempts to lower the circulating
concentrations of thymidine and deoxyuridine permanently
(la Marca et al. 2006; Lara et al. 2006). Allogenic stem cell
transplantation (SCT) has been more successful in correct-
ing the metabolic derangements: restoration of TP activity
was observed, and concentrations of thymidine and
deoxyuridine in plasma decreased to undetectable levels
(Hirano et al. 2006). SCT was the primary goal in the
treatment of our patient, despite the poor clinical condition.
Both siblings were considered as stem cell donors.
Although TP activities were in the heterozygous range,
we reasoned that this would be sufficient to correct the
metabolic derangements, as individuals with >8% residual
activity do not develop MNGIE syndrome (Marti et al.
2005). However, before the SCT procedure could be
initiated, the patient died.
The underlying mechanism as to why TP deficiency
presents in adulthood in most cases remains unclear. The
genetic defect and the subsequent metabolic derangement
are obviously present from the start of life. In vitro studies
with cultured skin fibroblasts of TP patients have shown
reduced cytochrome C oxidase (COX) activity (Nishigaki et
al. 2003). Immunocytochemical staining for the mtDNA-
encoded COX subunit 1 in fibroblasts of TP patients showed
a mosaic expression pattern, in contrast to that of control
fibroblasts, where the staining was uniform (Taanman et al.
2009). Furthermore, site-specific mtDNA point mutations
were detected in cultured skin fibroblasts of TP patients.
Multiple deletions and depletions were not detectable
(Nishigaki et al. 2003; Taanman et al. 2009). Only when
fibroblast were exposed to an excess of thymidine and
deoxyuridine over a longer period did the mtDNA content
decrease (Pontarin et al. 2006). When the nucleosides were
withdrawn, the mtDNA content returned to normal. This
phenomenon suggests a dose-accumulation effect in TP
deficiency before clinical symptoms occur, caused by
depletion or multiple deletions of the mtDNA.
Conclusion
TP deficiency is a multisystem, and ultimately fatal,
disease. The most promising cure is SCT and has to be
considered for all patients with TP deficiency. Transplan-
tation with stem cells from heterozygous siblings can, in
principle, correct the metabolic defect (Hirano et al. 2006).
It can be expected that all the reversible clinical symptoms
will be resolved, because, so far, no patients with MNGIE-
like symptoms and heterozygous TP activities have been
described. Early detection of TP deficiency is therefore of
utmost importance, and we advocate the inclusion of
screening for elevated thymidine and deoxyuridine concen-
trations as markers for TP deficiency in neonatal screening
programmes.
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